WTWH Media, the parent company of Drug Discovery & Development, announced on July 13 that it has renamed itself Arrowfly. The change applies to the corporate entity. DDD keeps its name, its URL, its newsletter, its editorial staff and its archives.
The Cleveland-based company operates more than 40 B2B media brands and more than 45 industry events across three networks, spanning engineering; healthcare and life sciences; and food, retail and hospitality. Drug Discovery & Development sits in the healthcare and life sciences network, alongside brands serving the. medical device sector, health systems, senior care and behavioral health.
“We built this company by earning the trust of professionals in industries where editorial authority matters,” said Matt Logan, CEO of Arrowfly in a statement. “The name is new, but the foundation is the same: editors who speak each industry’s language, events that connect buyers and sellers who would never meet otherwise, and communities that professionals rely on for the insight and intelligence they need to make real decisions.”
The rebrand follows a 2022 strategic partnership with Mountaingate Capital and subsequent acquisitions that expanded the company’s footprint in healthcare and life sciences. Logan, a B2B media executive with more than 25 years in the industry, became CEO in 2025.
More information is available at arrowfly.com.
Filed Under: Drug Discovery
